Skip to content
    Eli Lilly and Company logo

    Eli Lilly and Company

    Indianapolis, Indiana, United StatesFounded 1876
    www.lilly.comLinkedIn
    Biotech & Life SciencesHealthcare

    Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana, founded in 1876. Through its corporate venture arm, Lilly Ventures, it invests in biotech and healthcare companies at early to expansion stages, providing portfolio companies access to laboratory infrastructure, scientific talent, and global clinical and commercial networks.

    61% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $73.5M (across 125 rounds with reported amounts).

    Find people at Eli Lilly and Company on Goldilocks AI

    Portfolio

    121

    Fund Size

    $300M

    Top Stage

    Series A

    Last 12 Mo

    14

    Team

    VE

    Vicky Erwin

    Managing Director of Public Investments and acting Deputy CIO of Pension and Benefits

    BR

    Brad Robling

    Lilly Ventures Global Head

    BR

    Brad Robling

    Lilly Ventures Global Head

    NN

    Nisha Nanda

    Lilly Ventures

    NN

    Nisha Nanda

    Lilly Ventures

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    150 investments
    CompanyRoundAmountDate
    NextCure logoNextCureSeries B$500MAug 2026
    UUpDoc, Inc.Seed$18MJun 2026
    Terns Pharmaceuticals logoTerns PharmaceuticalsSeries C$87MMay 2026
    Incyclix Bio logoIncyclix BioSeries B$5MApr 2026
    CCrossbowSeries B—Mar 2026
    BreezeBio logoBreezeBioSeries B—Feb 2026
    TTRexBio, Inc.Series C$50MJan 2026
    Juvena Therapeutics logoJuvena TherapeuticsSeries B$33.5MJan 2026
    Recludix Pharma logoRecludix PharmaUnknown—Jan 2026
    Trex Bio logoTrex BioUnknown$50MJan 2026
    SanegeneBio logoSanegeneBioSeries B$110MJan 2026
    Gate Bioscience logoGate BioscienceSeries B$65MNov 2025
    Trogenix logoTrogenixSeries A—Oct 2025
    Trogenix logoTrogenixSeries A$70MOct 2025
    DDualitasSeries A$65MSep 2025
    Dualitas Therapeutics logoDualitas TherapeuticsSeries A$65MSep 2025
    Strand Therapeutics logoStrand TherapeuticsGrowth—Aug 2025
    LLaverock TherapeuticsSeed—Jun 2025
    Laverock logoLaverockSeed—Jun 2025
    Therini Bio logoTherini BioSeries A$39MMay 2025
    Stylus Medicine logoStylus MedicineSeries A$45MMay 2025
    Haya Therapeutics logoHaya TherapeuticsSeries A$65MMay 2025
    Grove Biopharma logoGrove BiopharmaSeries A$30MApr 2025
    Solu logoSoluSeries A$41MApr 2025
    SSolu TherapeuticsSeries A$41MApr 2025
    Page 1 of 6

    Top Co-Investors

    Alexandria Venture Investments28 shared
    Polaris Partners14 shared
    RA Capital Management14 shared
    Pfizer Ventures14 shared
    OrbiMed12 shared
    Catalio Capital Management12 shared
    ARCH Venture Partners10 shared
    Forbion9 shared
    Versant Ventures9 shared
    The Invus Group, LLC8 shared
    SV Health Investors8 shared
    Insight Partners7 shared
    Bristol Myers Squibb7 shared
    Samsara BioCapital7 shared
    BGF7 shared
    Sofinnova Partners7 shared
    Cowen Healthcare Investments6 shared
    Perceptive Advisors6 shared
    Gaingels6 shared
    T. Rowe Price6 shared

    Last updated: 7 October 2026